BHC - Bausch Health Companies Inc.

NYSE - NYSE Delayed Price. Currency in USD

Bausch Health Companies Inc.

2150 St. Elzear Boulevard West
Laval, QC H7L 4A8
Canada
514-744-6792
http://www.bauschhealth.com

SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Full Time Employees21,100

Key Executives

NameTitlePayExercisedYear Born
Mr. Joseph C. PapaCEO & Chairman5.4MN/A1955
Mr. Paul S. HerendeenExec. VP & CFO3.04MN/A1956
Ms. Christina M. AckermannExec. VP & Gen. Counsel2.3MN/A1965
Mr. Thomas J. AppioPres & Co-Head Bausch + Lomb/International2.63MN/A1962
Mr. Joseph GordonPres & Co-Head Bausch + Lomb/International1.24MN/A1964
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Bausch Health Companies Inc. develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb/International segment offers products with a focus on the vision care, surgical, and consumer and ophthalmology Rx products in the United States; and Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Salix segment provides gastroenterology products in the United States. The Ortho Dermatologics segment offers dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment provides pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. was founded in 1983 and is headquartered in Laval, Canada.

Corporate Governance

Bausch Health Companies Inc.’s ISS Governance QualityScore as of July 29, 2019 is 4. The pillar scores are Audit: 5; Board: 1; Shareholder Rights: 4; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.